Drug intelligence / Profile preview

IBI389

Development stage: Phase 1
Lead developer: Innovent Biologics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IBI389 is a bispecific antibody that targets both CD3-expressing T cells and Claudin 18.2 (CLDN18.2)-expressing cancer cells. It induces immune synapse formations, leading to T-cell activation and cytolytic protein production, which results in tumor cell lysis. Developed by Innovent Biologics, IBI389 is primarily indicated for advanced malignancies, including pancreatic ductal adenocarcinoma (PDAC) and gastric cancer.

Brand names: IBI389IBI-389IBI 389
Other names: Claudin18.2/CD3 Bispecific Antibody

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on IBI389.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBI389.

Explore the full profile